Ann: Change in substantial holding, page-11

Doublel, if I understand this right, they cannot buy at the moment, because they are insiders all the time they are negotiating the commercialization of PBT2. They have a lot of options, however, and for these, there is plenty of time left.
IMO, PBT2 is so valuable for the world that it will get to the market one day. It will save many lives and reduce the cost of these infections to societies. It is also valuable to the Antibiotic resistance fund. It needs this kind of molecule if it wants to be a major player in the fight against antibiotic-resistant bacteria, the task the purpose the Fund has established for. Pharma companies need PBT2, too. PBT2 will produce a lot of new business for them. ATH needs PBT2 business to get above 1 dollar in NASDAQ and we investors, most of all, need to get the share price much higher to become happy. Now the value of PBT2 is $ 0 or almost negative but it should be not millions but billions, IMO.